MSH2 Loss

CI-VAR-00002480Explore in graph →CIViC 808

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Neoplasm1
MSH2 Loss OR MLH1 Loss	Nivolumab	Predictive	B	Supports Sensitivity Response	4	accepted	EID11677 In this NCI-MATCH trial, 42 patients with 19 different cancers, none of which were colorectal, harbouring MMR deficiency defined by MLH1 or MSH2 loss were treated with Nivolumab. The three most common… (full text at CIViC) PMID 31765263 · Azad et al., 2020 · Open in CIViC	civic
Transitional Cell Carcinoma1
MSH2 Loss	Anti-PD-1 Monoclonal Antibody MEDI0680 + DurvalumabCombination	Predictive	C	Supports Sensitivity Response	3	accepted	EID1877 Case report of a 45-year old woman of Japanese descent with recurrent urothelial carcinoma. The patient was identified to harbor mutations in MSH2 (A913fs2, E226, E580*) and in MSH6 (R361H) by panel…

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.